의약품용 시클로덱스트린 시장 : 제품 유형별, 투여 경로별, 치료 영역별, 용도별 - 세계 예측(2026-2032년)

The Cyclodextrin in Pharma Market was valued at USD 1.38 billion in 2025 and is projected to grow to USD 1.50 billion in 2026, with a CAGR of 6.86%, reaching USD 2.20 billion by 2032.

Establishing the foundational rationale for cyclodextrin adoption across formulation development, regulatory pathways and clinical translation in modern therapeutics

Cyclodextrins have evolved from niche excipients to critical formulation enablers across modern pharmaceutical development, underpinning advances in solubility enhancement, targeted delivery and stability improvement. This introduction synthesizes the physicochemical rationale for cyclodextrin use, emphasizing molecular inclusion complexation, safety profiles across various beta and gamma homologues, and the expanding portfolio of modified derivatives that broaden application possibilities. It maps how these attributes translate into practical formulation levers that enable previously intractable APIs to achieve clinically viable bioavailability and acceptable patient experience.

The narrative begins by framing cyclodextrins within the lifecycle of drug development, from preformulation screening through late-stage manufacturing. It then addresses the interplay between formulation performance and regulatory expectations, noting how excipient provenance, impurity controls and sterilization considerations influence selection across parenteral, ophthalmic and other sensitive administration routes. Finally, the introduction sets out the analytical perspective taken in this report: pragmatic, scientifically grounded, and oriented toward decision-relevant implications for formulation scientists, regulatory leads and commercial strategists. By establishing this baseline, readers are prepared to interpret subsequent sections that explore market dynamics, segmentation nuances and regional policy impacts.

How derivative chemistry, regulatory evolution, and delivery innovation are reshaping excipient selection and development strategies across pharmaceutical pipelines

The cyclodextrin landscape is undergoing transformative shifts driven by advances in derivative chemistry, heightened regulatory scrutiny and cross-disciplinary innovation in drug delivery design. Modified cyclodextrins such as hydroxypropyl and sulfobutyl derivatives are increasingly preferred when conventional beta cyclodextrins do not meet solubility or safety constraints, and ongoing synthetic refinements are enhancing batch consistency and functional performance. Concurrently, innovators are integrating cyclodextrin-based strategies into targeted delivery constructs and controlled-release systems, leveraging inclusion complexation to modulate release kinetics and reduce off-target exposure.

Regulatory pathways are evolving in parallel, with agencies placing greater emphasis on excipient characterization, impurity profiling and clinical justification for novel excipient use. This regulatory tightening is accelerating demand for well-documented safety packages and harmonized quality standards for both natural and modified cyclodextrin variants. Moreover, the industry is witnessing a shift in clinical formulation priorities: there is higher tolerance for advanced excipients when they demonstrably reduce toxicities, enable less invasive routes of administration, or materially improve patient adherence. Together, these forces are reshaping R&D investment patterns, supplier relationships and the types of technical dossiers now expected by regulators and contract manufacturers alike.

Assessing the strategic and operational ramifications of United States tariff measures implemented in 2025 on pharmaceutical excipient sourcing, supply chain resilience and contractual risk

The imposition of new tariffs in 2025 by the United States introduced a compounding factor for global pharmaceutical supply chains that has practical implications for excipient sourcing, pricing dynamics and contractual risk allocation. Tariff pressures have prompted manufacturers to reassess supplier diversification and to scrutinize total landed cost rather than unit price alone. As a result, procurement teams are integrating customs duty scenarios into supplier qualification criteria, and legal teams are updating master supply agreements to reflect potential duty pass-through or mitigationclauses.

Operational responses to tariff-induced disruption include nearshoring certain production steps, qualifying secondary suppliers in tariff-exempt jurisdictions, and adjusting inventory policies to preserve clinical supply continuity. Formulation groups are also re-evaluating backward integration options for key excipients where strategic control reduces exposure to cross-border policy volatility. Importantly, these adaptations are not isolated; they have cascading effects on development timelines, CMO selection, and capital allocation for manufacturing assets. In aggregation, the tariff environment of 2025 has intensified focus on supply chain resilience planning, regulatory harmonization for excipient acceptance, and the need for closer collaboration between commercial, manufacturing and regulatory teams to keep development programs on schedule.

Dissecting product-type, administration route, functional application, and therapeutic-area segmentation to align cyclodextrin selection with technical and regulatory priorities

A nuanced segmentation analysis reveals distinct implications across product types, administration routes, applications and therapeutic areas that stakeholders must account for when prioritizing development activities. Product-type distinctions between modified and natural cyclodextrins influence both formulation strategy and regulatory substantiation: modified variants such as hydroxypropyl beta, methyl beta and sulfobutyl ether beta offer tailored solubility and safety profiles, while natural alpha, beta and gamma cyclodextrins retain relevance where simpler inclusion complexation suffices. These chemical choices cascade into processing considerations and impurity control strategies that affect downstream manufacturing and analytical burden.

Route-of-administration segmentation underscores how performance requirements diverge by clinical intent. Nasal applications require formulations compatible with drops and sprays that balance residence time and mucosal tolerability; ophthalmic use is narrowly focused on drop formulations demanding stringent sterility and ocular tolerance; oral delivery spans liquid and solid presentations, where liquids include suspensions and syrups and solids encompass capsules, powders and tablets with differing excipient interactions; parenteral routes, specified as intramuscular and intravenous, impose the highest sterility and impurity standards; and topical preparations, delivered as creams, gels and ointments, emphasize local tolerance and vehicle compatibility. Application-driven segmentation further clarifies development priorities: when cyclodextrins are leveraged for drug delivery systems the focus shifts to controlled and targeted delivery architectures, with controlled-release programs evaluating both extended and sustained release strategies; when the priority is solubility enhancement or stability improvement the chief concerns are complexation efficiency and degradation pathways; and when taste masking is central to patient acceptance, sensory testing and excipient selection become predominant.

Therapeutic-area segmentation links formulation imperatives to clinical endpoints and safety tolerances. Cardiovascular applications gravitate toward antihypertensive and lipid lowering agents where systemic exposure and long-term safety are paramount. Central nervous system programs, including antidepressants and neuroprotective agents, require consideration of blood-brain barrier permeability and excipient influence on CNS pharmacokinetics. Infectious disease workstreams that involve antibiotic and antiviral agents can prioritize high-concentration aqueous formulations or targeted delivery to infected tissues, while oncology preparations-spanning chemotherapeutic and immunotherapy agents-must reconcile potent APIs with excipient-mediated modulation of toxicity and delivery to tumor microenvironments. Understanding these intersecting segmentation layers enables teams to align formulation pathways, analytical strategies and clinical development plans with both scientific feasibility and regulatory expectations.

How geographic regulatory expectations, manufacturing capabilities, and procurement practices across the Americas, Europe Middle East & Africa, and Asia-Pacific shape cyclodextrin strategy and commercialization

Regional dynamics exert a significant influence on sourcing, regulatory strategy and commercial adoption, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct operational and policy landscapes. In the Americas, regulatory frameworks emphasize well-documented excipient safety and quality, and procurement practices increasingly favor supplier transparency, traceability and the ability to support sterile pharmaceutical supply chains. This region also shows rapid adoption of advanced formulation approaches when clinical benefits are clear and supported by robust data packages.

Within Europe, the Middle East & Africa, stakeholders contend with a wide range of regulatory sophistication and market access pathways. European regulatory agencies have stringent excipient characterization expectations, which encourages centralized dossiers and harmonized quality standards, while markets within the Middle East and Africa may present varied acceptance criteria, necessitating adaptive regulatory strategies and flexible commercial models. In contrast, the Asia-Pacific region is characterized by both manufacturing scale and active innovation, with many suppliers offering a broad array of modified cyclodextrin chemistries. Regional policy priorities in Asia-Pacific include local manufacturing incentives and an emphasis on export competitiveness, which can create advantages for companies able to align supply strategies with local regulatory and industrial policies. Cross-regionally, companies are responding by tailoring supply chain architectures, regulatory submissions and commercial engagement to the idiosyncrasies of each geographic cluster, thereby optimizing access to clinical and commercial opportunities while mitigating policy and logistical risk.

Examining how product innovation, regulatory documentation, manufacturing scale, and strategic partnerships differentiate companies competing in the cyclodextrin value chain

Key company insights reveal that competitive differentiation in the cyclodextrin space derives from integrated capabilities across chemistry innovation, quality systems, regulatory support and supply-chain robustness. Leading organizations are those that pair technically differentiated product portfolios with documented impurity control, scalable GMP manufacturing and proactive regulatory engagement. Alliances between excipient suppliers and pharmaceutical developers are increasingly strategic rather than transactional, with suppliers often providing formulation support, toxicology packages and regulatory-facing documentation to accelerate adoption of novel cyclodextrin derivatives.

Innovation leaders also invest in application-specific performance data, demonstrating how particular cyclodextrin grades perform in ophthalmic, parenteral or oral matrices, and how they interact with API classes relevant to cardiovascular, CNS, infectious disease and oncology programs. Contract manufacturers and finished-dose partners that can accommodate sterile processing and complex analytical requirements for parenteral and ophthalmic applications command strategic importance. Finally, companies that maintain geographically diversified manufacturing footprints and transparent supply chains are better positioned to respond to policy shifts and tariff pressures, providing customers with continuity of supply and the technical support necessary to de-risk development programs.

Actionable strategic initiatives to harmonize formulation science, procurement resilience, and regulatory readiness for cyclodextrin-enabled development programs

Industry leaders can extract tangible benefits by adopting a set of actionable initiatives that align science, supply and commercial strategy. First, accelerate cross-functional alignment between formulation scientists, regulatory leads and procurement teams to ensure excipient selections account for performance, compliance and sourcing risk simultaneously. Second, prioritize supplier qualification pathways that emphasize provenance, impurity control and sterile manufacturing capabilities for sensitive routes of administration, thereby reducing development uncertainty and potential regulatory queries.

Third, invest in targeted safety and application data for preferred cyclodextrin grades to build defensible dossiers that facilitate regulatory acceptance across diverse jurisdictions. Fourth, diversify sourcing strategies to include geographically distributed suppliers and to evaluate nearshoring or dual-sourcing where tariffs, logistics or geopolitical risk could threaten continuity. Fifth, embed scenario planning for policy shifts into procurement and development roadmaps so that duty impacts, customs delays or regulatory divergences can be anticipated and mitigated. By implementing these measures, organizations can reduce technical risk, shorten time-to-clinic for challenging APIs, and create more resilient supply chains that align with strategic growth priorities.

Methodological framework integrating expert interviews, regulatory analysis, analytical characterization, and supply-chain assessment to produce decision-ready insights

This research synthesizes primary interviews with formulation scientists, procurement leaders and regulatory specialists, augmented by secondary literature review of peer-reviewed publications, regulatory guidance documents and manufacturer technical dossiers. The approach prioritizes triangulation: insights derived from expert interviews were cross-validated against public regulatory positions and supplier technical specifications to ensure both scientific rigor and practical relevance. Attention was given to route-specific requirements and to the distinct analytical methodologies used to characterize inclusion complexes, residual solvents and potential impurities.

Analytical techniques considered include high-performance chromatography for derivative profiling, mass spectrometry for impurity identification, and in vitro dissolution and permeability assays to evaluate performance across oral, nasal, ophthalmic, parenteral and topical matrices. Regulatory review focused on excipient acceptance criteria, toxicology study expectations and sterility assurance levels applicable to parenteral and ophthalmic applications. Supply-chain assessment incorporated supplier audits, geographic footprint analysis and scenario modeling related to tariff exposure. Throughout, methodological choices emphasized reproducibility of findings, applicability to decision-makers, and clarity in translating technical data into operational recommendations.

Synthesis of technical, regulatory, and supply-chain imperatives that determine successful cyclodextrin deployment across formulation and therapeutic priorities

In conclusion, cyclodextrins occupy a pivotal position at the intersection of formulation innovation and regulatory stewardship, providing pragmatic pathways to address solubility, stability and delivery challenges across therapeutic areas. The interplay between modified and natural cyclodextrin chemistries, the constraints imposed by different routes of administration, and the tailoring required for specific clinical applications underscore the importance of a disciplined, cross-functional approach to excipient selection. When companies align technical validation, regulatory documentation and resilient sourcing, they unlock the potential of cyclodextrins to enable therapeutic differentiation and improve patient outcomes.

Looking forward, success will hinge on the ability to generate application-specific performance evidence, to navigate evolving regulatory expectations for excipients, and to structure supply chains that are responsive to geopolitical and tariff-related risks. Firms that proactively invest in these capabilities will find cyclodextrins an increasingly valuable tool in the formulation toolbox, particularly for complex APIs and delivery modalities that demand both scientific precision and operational reliability.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cyclodextrin in Pharma Market, by Product Type

• 8.1. Modified
  • 8.1.1. Hydroxypropyl Beta
  • 8.1.2. Methyl Beta
  • 8.1.3. Sulfobutyl Ether Beta
• 8.2. Natural
  • 8.2.1. Alpha
  • 8.2.2. Beta
  • 8.2.3. Gamma

9. Cyclodextrin in Pharma Market, by Route Of Administration

• 9.1. Nasal
  • 9.1.1. Drops
  • 9.1.2. Sprays
• 9.2. Ophthalmic
• 9.3. Oral
  • 9.3.1. Liquid
    • 9.3.1.1. Suspensions
    • 9.3.1.2. Syrups
  • 9.3.2. Solid
    • 9.3.2.1. Capsules
    • 9.3.2.2. Powders
    • 9.3.2.3. Tablets
• 9.4. Parenteral
  • 9.4.1. Intramuscular
  • 9.4.2. Intravenous
• 9.5. Topical
  • 9.5.1. Creams
  • 9.5.2. Gels
  • 9.5.3. Ointments

10. Cyclodextrin in Pharma Market, by Therapeutic Area

• 10.1. Cardiovascular
  • 10.1.1. Antihypertensive Agents
  • 10.1.2. Lipid Lowering Agents
• 10.2. Central Nervous System
  • 10.2.1. Antidepressants
  • 10.2.2. Neuroprotective Agents
• 10.3. Infectious Diseases
  • 10.3.1. Antibiotic Agents
  • 10.3.2. Antiviral Agents
• 10.4. Oncology
  • 10.4.1. Chemotherapeutic Agents
  • 10.4.2. Immunotherapy Agents

11. Cyclodextrin in Pharma Market, by Application

• 11.1. Drug Delivery System
  • 11.1.1. Controlled Release
    • 11.1.1.1. Extended Release
    • 11.1.1.2. Sustained Release
  • 11.1.2. Targeted Delivery
• 11.2. Solubility Enhancement
• 11.3. Stability Improvement
• 11.4. Taste Masking

12. Cyclodextrin in Pharma Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Cyclodextrin in Pharma Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Cyclodextrin in Pharma Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Cyclodextrin in Pharma Market

16. China Cyclodextrin in Pharma Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Ashland Global Holdings Inc
• 17.6. BASF SE
• 17.7. Caldic B.V.
• 17.8. Cargill Incorporated
• 17.9. Cerbios-Pharma SA
• 17.10. CycloChem Technologies Pvt. Ltd.
• 17.11. CycloLab Ltd.
• 17.12. Daicel Corporation
• 17.13. Hebei Tianxu Biotechnology Co Ltd
• 17.14. Hubei Guangji Pharmaceutical Co Ltd
• 17.15. Jiangsu Zhiyuan Biotechnology Co Ltd
• 17.16. Kleptose
• 17.17. Kuraray Co Ltd
• 17.18. Ligand Pharmaceuticals Incorporated
• 17.19. Merck KGaA
• 17.20. Nihon Shokuhin Kako Co Ltd
• 17.21. Roquette Freres
• 17.22. Samyang Corporation
• 17.23. Shandong Binzhou Zhiyuan Biotechnology Co Ltd
• 17.24. Shandong Tianli Pharmaceutical Co Ltd
• 17.25. Shandong Xinda Biotechnology Co Ltd
• 17.26. Shandong Yunzhou Biotechnology Co Ltd
• 17.27. Shijiazhuang Hongwei Biotechnology Co Ltd
• 17.28. Sichuan Kelong Chemical Co Ltd
• 17.29. Tokyo Chemical Industry Co., Ltd.
• 17.30. Wacker Chemie AG
• 17.31. Wuhan Sinobiological Technology Co Ltd
• 17.32. Zhejiang Huakang Pharmaceutical Co Ltd
• 17.33. Zibo Qianhui Biological Technology Co Ltd
• 17.34. Zibo Shuangfeng Chemical Co Ltd
• 17.35. Zibo Zhenhua Chemical Co Ltd